Fu YY, Li WM, Cai HQ, Jiao Y. Landscape of transarterial chemoembolization represented interventional therapy for hepatocellular carcinoma. World J Gastrointest Surg 2024; 16(12): 3903-3906 [DOI: 10.4240/wjgs.v16.i12.3903]
Corresponding Author of This Article
Yan Jiao, MD, PhD, Doctor, Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, The First Hospital of Jilin University, No. 1 Xin-min Street, Changchun 130021, Jilin Province, China. lagelangri1@126.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Surg. Dec 27, 2024; 16(12): 3903-3906 Published online Dec 27, 2024. doi: 10.4240/wjgs.v16.i12.3903
Landscape of transarterial chemoembolization represented interventional therapy for hepatocellular carcinoma
Yang-Yang Fu, Wen-Mao Li, Hong-Qiao Cai, Yan Jiao
Yang-Yang Fu, Department of The First Operation Room, The First Hospital of Jilin University, Changchun 130000, Jilin Province, China
Wen-Mao Li, Department of Rehabilitation, The Second Hospital of Jilin University, Changchun 130000, Jilin Province, China
Hong-Qiao Cai, Yan Jiao, Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun 130021, Jilin Province, China
Author contributions: Jiao Y designed the overall concept and outline of the manuscript; Fu YY contributed to the discussion and design of the manuscript; Fu YY, Li WM, and Cai HQ contributed to the writing, and editing the manuscript, illustrations, and review of literature.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yan Jiao, MD, PhD, Doctor, Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, The First Hospital of Jilin University, No. 1 Xin-min Street, Changchun 130021, Jilin Province, China. lagelangri1@126.com
Received: August 29, 2024 Revised: September 23, 2024 Accepted: October 23, 2024 Published online: December 27, 2024 Processing time: 89 Days and 11.1 Hours
Abstract
This article discusses the article written by Tan et al. Transarterial chemoembolization (TACE) is one of the main treatment methods for advanced hepatocellular carcinoma (HCC). There are other vascular interventional therapies, including drug-eluting bead TACE, transarterial radioembolization, and hepatic arterial infusion chemotherapy. TACE combined with anti-angiogenesis therapy may improve tumor control and prolong progression free survival. The combination therapy of TACE and immunotherapy may improve the clinical efficacy of HCC. In future research, more basic and clinical studies are needed to explore the immunogenic intervention therapy.
Core Tip: The continuous development of transarterial chemoembolization represented interventional therapy technology and the constant updating of systemic drugs such as molecular targeted drugs and immune checkpoint inhibitors are changing the treatment pattern of primary hepatocellular carcinoma (HCC). The combination of interventional therapy and systemic therapy will become a new dawn for HCC treatment.
